Lucas Capital Management acquired a new position in shares of Novartis AG (NYSE:NVS) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,700 shares of the company’s stock, valued at approximately $232,000.
A number of other hedge funds have also made changes to their positions in the stock. Parnassus Investments CA grew its holdings in Novartis AG by 18.5% during the third quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock worth $811,095,000 after acquiring an additional 1,477,168 shares during the period. Bank of America Corp DE boosted its position in Novartis AG by 7.5% during the first quarter. Bank of America Corp DE now owns 7,328,730 shares of the company’s stock worth $544,304,000 after purchasing an additional 508,435 shares in the last quarter. Fisher Asset Management LLC boosted its position in Novartis AG by 2.0% during the third quarter. Fisher Asset Management LLC now owns 6,632,984 shares of the company’s stock worth $569,442,000 after purchasing an additional 127,049 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Novartis AG by 3.1% during the second quarter. The Manufacturers Life Insurance Company now owns 5,036,427 shares of the company’s stock worth $420,390,000 after purchasing an additional 151,115 shares in the last quarter. Finally, BlackRock Inc. boosted its position in Novartis AG by 25.3% during the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock worth $296,299,000 after purchasing an additional 717,186 shares in the last quarter. 11.00% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/13/lucas-capital-management-takes-232000-position-in-novartis-ag-nvs.html.
Novartis AG (NVS) traded down $0.10 during trading on Monday, reaching $82.38. The company had a trading volume of 1,182,500 shares, compared to its average volume of 2,350,100. The firm has a market capitalization of $216,200.00, a price-to-earnings ratio of 17.34, a P/E/G ratio of 2.63 and a beta of 0.72. Novartis AG has a 52-week low of $66.93 and a 52-week high of $86.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81.
Novartis AG (NYSE:NVS) last released its earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04. The firm had revenue of $12.41 billion during the quarter, compared to analyst estimates of $12.21 billion. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.23 earnings per share. equities research analysts forecast that Novartis AG will post 4.75 EPS for the current fiscal year.
A number of analysts have commented on NVS shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Monday, July 17th. Cowen and Company reiterated a “hold” rating on shares of Novartis AG in a research report on Tuesday, July 18th. Morgan Stanley upgraded Novartis AG from an “underweight” rating to an “overweight” rating in a research report on Wednesday, July 26th. BidaskClub downgraded Novartis AG from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, Zacks Investment Research upgraded Novartis AG from a “hold” rating to a “buy” rating and set a $96.00 target price on the stock in a research report on Tuesday, September 19th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $85.32.
Novartis AG Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.